tirzepatide kidney disease SURPASS-4: slows in adults with type 2 diabetes, CV risk It's important to study the

According to the Summary of Product Characteristics (SmPC), these include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea (very common) Decreased appetite (very common) Vomiting (common, affecting up to 1 in 10 people) Constipation (common) Abdominal pain (common) Dyspepsia (common) Cholelithiasis (common) Headache (common) These gastrointestinal effects typically occur during the initial weeks of treatment or following dose escalation, and often diminish over time as the body adjusts to the medication

If you experience persistent night sweats, it is a sign that your dosage or meal timing may need adjustment by your healthcare provider to prevent nocturnal blood sugar dips

Tirzepatide is administered once a week

Time NAD in the morning